Jingqing is responsible for covering a subset of cardiovascular and eye disease research. She is also responsible for scientific due diligence for RTW’s portfolio company, JIXING.
Prior to joining RTW, Jingqing led business development efforts with the strategy group at GenScript. Previously, she held senior R&D and operational positions at various start-ups, including Nima (Co. acquired), and her own company, Aebeca (Co. acquired). Jingqing received her PhD in chemical engineering from MIT, where she conducted research on biological applications for fluorescent nanomaterials.
I feel privileged to work with an incredibly talented and dedicated team to accelerate the process of bringing novel therapeutics to patients.